Clinical Trial Update: DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)

View source ↗

Summary

A DAHANCA trial update evaluating the prognostic value of the PET tracer 18F-FAZA in head and neck squamous cell carcinoma (HNSCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 18F-FAZA (fluorine-18 labeled nitroimidazole PET radiotracer)

Snippet

Sponsor: University of Aarhus | Conditions: Cancer of the Head and Neck | Status: COMPLETED